➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Last Updated: July 30, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Finerenone

Email this page to a colleague

« Back to Dashboard

What is the drug development status for Finerenone?

Finerenone is an investigational drug.

There have been 11 clinical trials for Finerenone. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2015.

The most common disease conditions in clinical trials are Kidney Diseases, Diabetes Mellitus, Type 2, and Diabetes Mellitus. The leading clinical trial sponsors are Bayer and [disabled in preview].

There are thirty-one US patents protecting this investigational drug and four hundred and eighty-nine international patents.

Recent Clinical Trials for Finerenone
A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy, DR)BayerN/A
Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone on Morbidity (Events Indicating Disease Worsening) and Mortality (Death Rate) in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood BayerPhase 3
Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male VolunteersBayerPhase 1

See all Finerenone clinical trials

Clinical Trial Summary for Finerenone

Top disease conditions for Finerenone
Top clinical trial sponsors for Finerenone

See all Finerenone clinical trials

US Patents for Finerenone

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Finerenone ⤷  Free Forever Trial Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro- 1-6-naphthyridine-3-carbox-amide and the purification thereof for use as an active pharmaceutical ingredient BAYER PHARMA AG (Berlin, DE) ⤷  Free Forever Trial
Finerenone ⤷  Free Forever Trial Substituted N-bicyclo-2-aryl-quinolin-4-carboxamides and use thereof BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE) ⤷  Free Forever Trial
Finerenone ⤷  Free Forever Trial Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Free Forever Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Finerenone

Drugname Country Document Number Estimated Expiration Related US Patent
Finerenone Argentina AR101403 2034-08-01 ⤷  Free Forever Trial
Finerenone Australia AU2015295376 2034-08-01 ⤷  Free Forever Trial
Finerenone Brazil BR112017001678 2034-08-01 ⤷  Free Forever Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.